Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The Centers for Medicare & Medicaid Services said it’s issuing a nationwide moratorium on new providers entering the spaces until it has a chance to look into allegations of fraud, waste and abuse. It confirmed investigations of various organizations are pending.
Private-equity acquisitions of primary-care provider practices neither alter hospitalization rates nor affect acute-care outcomes, according to new research out of Brown University.
Epic makes the list with its enterprise inpatient EHR and related platforms. So does PCC, aka Physician’s Computer Company, which supplies pediatric-specific ambulatory EHR and practice-management products and services.
In a survey, employers told the Business Group on Health that they aren’t yet seeing evidence of long-term health benefits from taking GLP-1s for weight loss, leaving them unsure how to manage costs while continuing to cover them.
Liberator Medical Supply was accused of offering doctors kickbacks, such as discounted and free supplies, in exchange for filling prescriptions with its products.
The last count submitted to HHS in October pegged the number at 100 million. Now that figure sits at 190 million, and the company continues its investigation.
The Centers for Medicare & Medicaid Services appealed a court ruling that ordered the agency to change the star rating for UnitedHealthcare's Medicare Part D plans, which had been reduced due to a disputed phone call. CMS has now dropped the appeal.
When Larry Ellison talks about healthcare AI, people invest. At least, that’s what happened after the Oracle chairman enthused over AI’s potential to cook up vaccines for cancer.
Tim Noel is taking the reins of the insurance giant in the aftermath of the murder of its previous CEO, Brian Thompson. Noel has been with the company since 2007.
The agency found 82 cases of anaphylaxis associated with glatiramer acetate, sold under the brand names Copaxone and Glatopa, including 19 that emerged after patients had been taking these drugs for more than a year.